Orpha Labs AG Announces the Initiation of a Phase III Trial Evaluating ORL-101 for Treatment of Leukocyte Adhesion Deficiency Type II

Teva Pharmaceutical Industries Limited recently announced that the FDA has approved expanded use of its branded product, Uzedy (risperidone).

The FDA has granted breakthrough therapy designation (BTD) to the investigational B-cell lymphoma 2 (BCL2) inhibitor sonrotoclax (BGB-11417) for the treatment of adult patients...

Cedars-Sinai investigators have identified a "molecular switch" on a gene strongly associated with the autoimmune disease lupus, which appears to propel immune cells into overdrive, attackin...

Tvardi Therapeutics’ stock has crashed more than 80% after the company revealed that its idiopathic pulmonary fibrosis (IPF) candidate flunked in a Phase II trial.